Stay updated on NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer
Sign up to get notified when there's something new on the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page.

Latest updates to the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page’s interface revision/version label was updated from “v3.5.2” to “v3.5.3,” indicating a minor update to the ClinicalTrials.gov site software rather than a change to the trial record content.SummaryDifference0.0%

- Check23 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check51 days agoChange DetectedFooter revision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check58 days agoChange DetectedFooter revision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check88 days agoChange DetectedVersion 3.4.2 (2026-02-03) adds Contacts/Locations and Study Status to the record history. The prior revision 3.4.0 (2025-10-06) was removed.SummaryDifference0.3%

- Check102 days agoChange DetectedAdded a glossary toggle and a color-coded change legend; updated revision to v3.4.0 and removed the No FEAR Act Data and the v3.3.4 entry.SummaryDifference0.5%

Stay in the know with updates to NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer
Enter your email address, and we'll notify you when there's something new on the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page.